摘要
目的 探讨血清微囊蛋白-1(Caveolin-1)、半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)与急性缺血性卒中(AIS)患者早期神经功能恶化(END)的关系。方法 选取AIS患者148例为AIS组,根据其是否发生END分为END组(n=57)、非END组(n=91);同期选取体检健康者53例为对照组。收集各组临床资料,用酶联免疫吸附法检测血清Caveo-lin-1、Caspase-3。多因素Logistic回归分析AIS患者发生END的影响因素,受试者工作特征曲线分析血清Caveolin-1、Caspase-3水平对AIS患者发生END的预测价值。结果 AIS组血清Caveolin-1、Caspase-3水平高于对照组(P均<0. 05)。美国国立卫生研究院卒中量表评分、血糖、Caveolin-1、Caspase-3为AIS患者发生END的影响因素(P均<0. 05)。Caveo-lin-1联合Caspase-3预测AIS患者发生END的曲线下面积大于二者单独预测(P均<0. 05)。结论 AIS患者血清Caveo-lin-1、Caspase-3水平升高为END发生的独立危险因素,二者可作为END发生的预测指标。
Objective To investigate the relationships between serum Caveolin-1,Caspase-3 and early neurological deterioration(END)in patients with acute ischemic stroke(AIS).Methods Totally 148 patients with AIS were selected as the AIS group,and then they were divided into the END group(n=57)and non-END group(n=91)according to whether they had END.Fifty-three healthy people were selected as the control group in the same period.The clinical data of each group were collected,and the serum Caveolin-1 and Caspase-3 were detected by enzyme-linked immunosorbent assay.Multivariate Logistic regression analysis was used to analyze the influencing factors of END in AIS patients,and the receiver operating characteristic curve was used to analyze the predictive value of serum Caveolin-1 and Caspase-3 levels for END in AIS patients.Results The levels of serum Caveolin-1 and Caspase-3 in the AIS group were higher than those in the control group(both P<0.05).National Institutes of Health Stroke Scale(NIHSS)score,blood glucose,Caveolin-1 and Caspase-3 were the influencing factors for END in AIS patients(all P<0.05).The area under the curve of Caveolin-1 combined with Caspase-3 in predicting END in AIS patients was greater than that of either one alone(P<0.05).Conclusion The elevated levels of serum Caveolin-1 and Caspase-3 in patients with AIS are independent risk factors for the occurrence of END,and they can be used as predictors of the occurrence of END.
作者
高靖
王秀艳
杨红梅
朱辰蕊
赵悦
张会芬
GAO Jing;WANG Xiuyan;YANG Hongmei;ZHU Chenrui;ZHAO Yue;ZHANG Huifen(General Practice,Tangshan Kailuan General Hospital,Tangshan 063000,China)
出处
《山东医药》
CAS
2022年第7期18-21,共4页
Shandong Medical Journal
基金
河北省医学科研课题(20190830)。